SCHEMBL14744771

SCHEMBL14744771

CCc1cc2c(OCc3ccccc3)c(C(=O)OC)ccc2n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
HPGD P15428 2/20 0.48
ALDH1A1 P00352 3/20 0.43
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 2/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
SRD5A2 P31213 2/20 0.41
NR4A2 P43354 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
BRD4 O60885 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MAOB P27338 1/20 0.39
SRD5A1 P18405 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744993 0.79 LMNA (0.49) LMNAHPGDALDH1A1TSHRUSP2
SCHEMBL14744772 0.79 KDM4E (0.49) LMNAHPGDALDH1A1TSHRGAA
SCHEMBL19644367 0.76 NR4A2 (0.46) LMNAHPGDALDH1A1TSHRHSD17B10
SCHEMBL5280954 0.74 LMNA (0.60) LMNAHPGDALDH1A1TSHRUSP2
SCHEMBL3511761 0.73 LMNA (0.63) LMNAHPGDALDH1A1TSHRUSP2
SCHEMBL15726037 0.73 LMNA (0.58) LMNAHPGDALDH1A1TSHRUSP2
SCHEMBL28440767 0.72 NR4A2 (0.47) GAAMAPTNR4A2MEN1KMT2A
SCHEMBL19610526 0.72 HPGD (0.57) LMNAHPGDALDH1A1TSHRUSP2
SCHEMBL19732557 0.72 LMNA (0.57) LMNAHPGDALDH1A1TSHRUSP2
SCHEMBL22438895 0.71 HPGD (0.56) LMNAHPGDALDH1A1TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP LMNA 2119/4885HPGD 1279/4885ALDH1A1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.